CONNECT WITH US
HealthTech

HealthTech

After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire

Endpoints News logo

Published on

Add as a preferred source on Google
After Be Bio shutdown, its CEO heads to Orbis; Enanta's longtime chief Jay Luly to retire

Af­ter Be Bio shut­down, its CEO heads to Or­bis; Enan­ta's long­time chief Jay Lu­ly to re­tire

→ For­mer Be Bio­phar­ma chief Joanne Smith-Far­rell has land­ed at Or­bis Med­i­cines , an Eli Lil­ly – and No­vo -backed start­up that’s de­vel­op­ing oral …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Al San­drock to step down as Voy­ager CEO; In­smed adds Paul Hud­son to board October 23, 2026

Ex-Genen­tech sci­en­tist joins Ira Mell­man at Medici; In­tel­lia poach­es CMO from Schol­ar Rock October 16, 2026

Viking com­mer­cial chief is out in a hur­ry; Gilead looks to BeOne ex­ec for Chi­na ex­pan­sion October 9, 2026

Sanofi has no plans for a 'ma­jor' over­haul as Dupix­en­t's patent cliff looms

Se­tara gets $90M to con­tin­ue rare dis­ease pipeline spun out of Jaz­z's Ac­tio deal

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.